Straumann Holding AG
SIX:STMN
Straumann Holding AG
SIX:STMN
Price:
120 CHF
-0.29%
Market Closed
Updated:
May 15, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
26.5
Current
29.9
Median
12.9
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=26.5
Enterprise Value
/
19.1B
EBITDA
722.5m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| CH |
|
Straumann Holding AG
SIX:STMN
|
19.1B CHF | 26.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
180.9B USD | 19 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.3B USD | 56.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.5B USD | 23.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.1B USD | 14.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108B USD | 30.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.9B USD | 18.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.2B EUR | 18.7 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
375.2B CNY | 28.4 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
52B USD | 26.7 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.7B USD | 58.1 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
24
2-Years Forward
EV/EBITDA
20.9
3-Years Forward
EV/EBITDA
18.5
You don't have any saved screeners yet
